Retatrutide has emerged as a new pharmaceutical in the fight against obesity. This novel drug, classified as a dual GLP-1 and GIP receptor agonist, exhibits promising results in clinical trials. By stimulating these https://barbarauqyv782032.articlesblogger.com/58526207/tirzepatide-a-promising-new-treatment-for-obesity